HNI Corporation (HNI) – Form 4 insider transaction
Director Miguel M. Calado reported the sale of 1,743 HNI common shares on 07/24/2025 at a stated price of $53 per share. The trade was made under a Rule 10b5-1 plan adopted on 03/04/2025, indicating it was pre-scheduled. Following the sale, Calado’s direct ownership stands at 30,085.415 shares. No derivative security transactions were reported.
The filing shows an approximate reduction of about 5.5 % of Calado’s direct position (1,743 ÷ 31,828.415 pre-sale shares). Other than the transaction details, the Form 4 does not include additional financial or strategic disclosures.
HNI Corp. (HNI) – Form 4 insider activity: President & CEO Jeffrey D. Lorenger executed two small option exercises and corresponding open-market sales on 07/24/2025 under a Rule 10b5-1 plan adopted 11/06/2024.
- Exercised: 200 non-qualified options at an exercise price of $46.62, reducing his option balance to 45,850.
- Sold: 200 common shares at an average price of $53.29.
- Net effect: No change in direct share count; post-transaction direct ownership stands at 344,193.462 shares, plus 7,377.525 shares held indirectly via the Profit Sharing Retirement Plan.
The transactions represent less than 0.1 % of Mr. Lorenger’s direct holdings and appear routine, with proceeds likely used to cover taxes/costs. No material impact on share count or insider ownership structure is indicated.
HNI Corp. (HNI) director Miguel Calado has filed Form 144 for the planned sale of 1,743 common shares via Fidelity Brokerage on 24 Jul 2025. The filing lists an aggregate market value of $92,379; with 46,552,671 shares outstanding, the transaction equates to roughly 0.004 % of float, implying negligible dilution or control impact.
The shares were earned as board-fee compensation on 5 May 2015. Calado also sold 2,000 shares for $100,000 on 27 Jun 2025, signaling continued personal portfolio rebalancing. The notice contains no operational or financial guidance and expressly states the filer possesses no undisclosed material adverse information.